文献速递泌尿生殖与妇科肿瘤放疗

局部晚期宫颈癌患者接受小于全子宫照射

Less than whole uterus irradiation for patients with locally advanced cervical cancer.
PubMed 文献 · Radiother Oncol · 2024-03-02

单中心研究纳入2010至2022年109例FIGO IB–IVA期宫颈癌患者,接受同步放化疗(IMRT及近距离放疗),靶区仅包含大体宫颈肿瘤及内靶区并加5 mm PTV外扩。中位随访65个月,全队列2年局部复发累积 incidence 为4.2%(95%CI 1.3–9.7)。PTV包含子宫比例<75%者较≥75%者肠道D200cc显著更低(p=0.02),两组局部失败累积 incidence 无显著差异。

要点

  • PTV包含子宫<75%者肠道D200cc较≥75%者显著更低(p=0.02)。
  • 两组局部失败累积 incidence 无显著差异。
  • 作者认为小于全子宫照射似乎不损害局部控制,可考虑用于经仔细选择的宫颈癌患者。

核心结论

  • 对于宫颈癌根治性IMRT,包含小于全子宫似乎不损害局部控制。
  • 作者认为,小于全子宫照射可考虑用于经仔细选择的宫颈癌患者,以降低肠道剂量和可能的治疗相关毒性。

研究设计与样本

  • 单中心研究,纳入2010至2022年109例FIGO IB–IVA期宫颈癌患者,接受根治性同步放化疗,包括IMRT和近距离放疗。
  • 该中心做法为包含大体宫颈肿瘤及内靶区(考虑膀胱充盈差异),并加5 mm PTV外扩。
  • 采用竞争风险方法分析局部、区域和远处复发,并以PTV包含子宫的中位比例75%为切点,用Wilcoxon秩和检验评估基于PTV包含子宫比例的危险器官剂量差异。

主要发现

  • 中位随访时间65个月(范围3–352个月)。
  • 全队列2年局部复发累积 incidence 为4.2%(95%CI 1.3–9.7)。
  • 与PTV包含子宫≥75%的患者相比,PTV包含子宫<75%的患者肠道D200cc显著更低(p=0.02)。
  • 两组局部失败累积 incidence 无显著差异。

临床怎么用

  • 作者认为,小于全子宫照射可考虑用于经仔细选择的宫颈癌患者,以降低肠道剂量和可能的治疗相关毒性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Current consensus guidelines for definitive cervical cancer intensity modulated radiation therapy (IMRT) recommend inclusion of the entire uterus within the clinical target volume, however this is debated. We aimed to evaluate outcomes of patients with cervical cancer who were treated with less than whole uterus irradiation. METHODS: We identified 109 patients with FIGO Stage IB-IVA cervical cancer treated definitively with concurrent chemoradiation, including IMRT and brachytherapy, from 2010 to 2022 at a single institution where the practice was to include the gross cervix tumor with an internal target volume with differences in bladder filing accounted for, plus additional 5 mm planning target volume (PTV) margin. Local, regional, and distant recurrences were analyzed using competing risk methods, and a Wilcoxon rank sum test was performed to assess differences in dose to organs at risk based on the proportion of the uterus included in the PTV, with the median proportion of the uterus included (75 %) used as the cut-point. RESULTS: The median follow-up time was 65 months (range 3-352 months). The 2-year cumulative incidence of LR for the entire cohort was 4.2 % (95 % confidence interval [CI] 1.3-9.7). Compared with patients who had ≥ 75 % of the uterus included in the PTV, patients who had < 75 % of the uterus included in the PTV had significantly lower bowel D200cc (p = 0.02). The cumulative incidence of local failure (LR) was not significantly different between the two groups. CONCLUSIONS: Including less than the whole uterus for definitive cervix cancer IMRT does not seem to compromise local control. Less than whole uterus irradiation could be considered for carefully selected cervix cancer patients to decrease bowel dose and possible treatment-related toxicity.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Hui C, Ewongwo A, Mendoza MG, et al. Less than whole uterus irradiation for patients with locally advanced cervical cancer. Radiother Oncol. 2024. PMID: 38438017. doi:10.1016/j.radonc.2024.110199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。